Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

HROW US Equity

Harrow, Inc.Health Care · Pharmaceutical Preparations · CIK 1360214 · FY ends Dec 31
$41.64
+2.12 (+5.36%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-02in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 18 to our consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated into this Item by reference.

Item 9A · ICFR · Based on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · In connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2025, our disclosure controls and procedures were effective.

2024-12-312025-03-27in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 18 to our consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated into this Item by reference. Additionally, we have been in discussions with the federal government regarding past inspections at NJOF. For information regarding these discussions see Part I, Item 1A. “Risk Factors – We have been in discussions with the federal government regarding past FDA inspections of our 503B facility, and to the extent we are unable to demonstrate compliance with cGMPs and other required regulations, the government could seek injunctive remedies, including through a consent decree and temporary injunction, the effects of which could be costly to us and could result in adverse consequences to our business.”

Item 9A · ICFR · Based on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · In connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2024, our disclosure controls and procedures were effective.

2023-12-312024-03-19in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 18 to our consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated into this Item by reference.

Item 9A · ICFR · Based on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · In connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2023, our disclosure controls and procedures were effective.

2022-12-312023-03-23in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 18 to our consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated into this Item by reference.

Item 9A · ICFR · Based on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · In connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

2021-12-312022-03-10in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 18 to our consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated into this Item by reference.

Item 9A · ICFR · Based on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · In connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2021, our disclosure controls and procedures were effective.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.